Shares of Blueprint Medicines Corporation (BPMC) are falling more than 9% Wednesday morning after the company reported wider loss for the fourth-quarter that missed the Street view. The company's full-year revenue outlook also came in below consensus estimates.
The company reported net loss of $318.69 million or 5.40 per share for the fourth quarter compared with net loss of $85.67 million or 1.53 per share in the same quarter a year ago. On average, 14 analysts polled by Thomson Reuters were expecting loss of $1.65 per share.
Revenues were $107.0 million for the fourth quarter. The consensus estimate stood at $102.69 million.
Looking forward, the company expects revenue in the range of $180 million-$200 million in 2022. The consensus estimate stands at 210.91 million.
BPMC is at $75.12. It has been trading in the range of $66.29-$117.86 in the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.